BioCardia Reports First Quarter 2024 Business Highlights and Financial Results

SUNNYVALE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for th...

Related Keywords

United States ,Japan ,Maryland ,California ,France ,Canada ,French ,Japanese ,Peter Altman ,Biocardia Inc ,Maryland Stem Cell Research Fund ,European Society Of Cardiology Heart Failure Congress ,Medicaid Services ,Exchange Commission ,Device Agency ,Company Annual Report On Form ,Exchange Commission On ,Cell Therapy ,Ischemic Heart Failure ,Failure Trial ,Heart Failure Therapeutics ,Therapy Heart Failure ,Chronic Myocardial Ischemia ,Therapy Chronic Myocardial Ischemia Trial ,Excellent Phase ,European Society ,Cardiology Heart Failure Congress ,Therapy Heart Failure Trial ,Reduced Ejection Fraction ,Mesenchymal Stem Cell Therapy ,Therapy Trial ,Heart Failure ,Medical Device Agency ,Quarterly Report ,Consolidated Statements ,Consolidated Financial Statements ,Annual Report ,